JAK1 inhibition successful in hidradenitis suppurativa

The results of two phase 2 trials with a novel Janus kinase (JAK) 1 inhibitor showed a remarkable efficacy and a good safety profile in patients with moderate-to-severe hidradenitis suppurativa (HS). Patient with HS experience painful inflammatory lesions and have a markedly reduced quality of life. The rationale for using a JAK inhibitor in this indications is that treatments targeting proinflammatory cytokine signalling may influence disease pathology and ameliorate symptoms of HS. “There is an unmet medical need for an oral treatment for these patients,” said Dr Afsaneh Alavi (Mayo Cinic, USA) during the presentation of the results from two phase 2 studies with a JAK1 inhibitor [1]. INCB054707 is an oral small molecule JAK1 inhibitor with 52-fold greater selectivity for JAK1 versus JAK2. Study 1 was an open-label, single-arm study, and study 2 was a placebo-controlled, dose-escalation study in which 3 doses of the JAK inhibitor were tested (i.e. ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 30 October, 202018 December, 2020